Clinical Trial Update: Discovery of Sirolimus Sensitive Biomarkers in Blood [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sirolimus-sensitive biomarkers in the blood of patients with lymphangioleiomyomatosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Lymphangioleiomyomatosis | Phase 2 | Status: COMPLETED | Results posted: 2026-02-18